POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: JPinLA on August 07, 2007, 03:43:42 pm
-
I was reading through some papers today and came across this one in PNAS from a group at Trimeris:
http://www.pnas.org/cgi/content/full/104/31/12772
Very early development work in improving fusion inhibitors (like Fuzeon) with more potent forms of the peptides. At least in vitro they seem to work with virus that has developed resistance to other therapies and that resistance to the new forms of the peptides requires a lot more mutations for decreased sensitivity - again in vitro.
Looks like they are in early preclinical testing but they do look promising for enahnced therapeutics down the line and are strong candidates for clinical developement.
Some good basic science here on HIV drug development research. We'll see how it pans out. Not sure what the success/failure has been with Fuzeon but the basic principle of the therapeutis seems very attractive.
JP